Clinical Trial

Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients

Study acronym: SHPD002
Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The investigators hypothesize that paclitaxel combined with cisplatin in a weekly-based regimen as neoadjuvant chemotherapy is effective and tolerable for locally advanced breast cancer. In patients with some sub-type advanced breast cancer, neo-adjuvant chemotherapy combined with endocrine therapy may improve the pathological remission rate. Premenopausal patients with triple negative breast caner and hormonal receptor positve breast cancer patients will be randominzed to have neoadjuvant chemotherapy combined with endocrine therapy or not.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2014-08-20; most recent amendment 2023-08-25.
Status change: Recruiting → Active, Not Recruiting 2019-03-13
Trial Details
NCT Number NCT02221999
Lead Sponsor RenJi Hospital
Conditions Tubular Breast Cancer, Mucinous Breast Cancer, Invasive Ductal Breast Cancer, Inflammatory Breast Cancer
Enrollment 250 participants
Start Date 2013-09
Primary Completion 2019-01 (estimated)
Study Completion 2029-01 (estimated)
Updated on ClinicalTrials.gov 2023-08-29